$SNY Cashflow Statement | Understand Stock

$SNY

$41.79 +$0.19 (0.46%) Close

$SNY Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of EUR, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from (used in) operating activities [abstract]
Net income attributable to equity holders of Sanofi
Net income excluding the exchanged/held-for-exchange Animal Health business
Net income attributable to non-controlling interests
Share of undistributed earnings from investments accounted for using the equity method
Depreciation, amortization and impairment of property, plant and equipment, right-of-use assets and intangible assets
Gains and losses on disposals of non-current assets, net of tax
Gain on Regeneron investment arising from transaction of May 29, 2020, net of tax
Net change in deferred taxes
Net change in non-current provisions and other non-current liabilities
Cost of employee benefits (stock options and share-based payments)
Impact of the workdown of acquired inventories remeasured at fair value
Other profit or loss items with no cash effect on cash flows generated by operating activities
Operating cash flow before changes in working capital

Adjustments to reconcile profit (loss) [abstract]
(Increase)/decrease in inventories
(Increase)/decrease in accounts receivable
Increase/(decrease) in accounts payable
Net change in other current assets and other current liabilities
Cash flows from (used in) operating activities, continuing operations
Net cash provided by/(used in) operating activities
Cash flows from (used in) operating activities, discontinued operations
Cash flows from (used in) investing activities [abstract]
Net cash provided by/(used in) operating activities of the discontinued Opella business
Acquisitions of consolidated undertakings and investments accounted for using the equity method
Acquisitions of other equity investments
Disposal of consolidated undertakings and investments accounted for using the equity method, net of tax
Net proceeds from sale of Regeneron shares on May 29, 2020
Net change in other non-current assets
Cash flows from (used in) investing activities, continuing operations
Net cash provided by/(used in) continuing investing activities
Net cash inflow from the exchange of the Animal Health business for BI’s Consumer Healthcare business
Cash flows from (used in) investing activities, discontinued operations
Net cash inflow from the Opella transaction

Cash flows from (used in) financing activities [abstract]
Net cash provided by/(used in) investing activities of the discontinued Opella business (h)
Dividends paid:
to shareholders of Sanofi
to non-controlling interests, excluding BMS
Payments received/(made) on changes of ownership interest in a subsidiary without loss of control
Additional long-term debt contracted
Repayments of long-term debt
Repayments of lease liabilities
Net change in short-term debt and other financial instruments
Acquisitions of treasury shares and related tax effect
Cash flows from (used in) financing activities, continuing operations
Net cash provided by/(used in) continuing financing activities
Cash flows from (used in) financing activities, discontinued operations
Impact of exchange rates on cash and cash equivalents
Effect of Reclassification of Discontinued Operation
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes
Cash and cash equivalents, beginning of period
Cash and cash equivalents at end of period
Cash and cash equivalents, discontinued operations

Comments